Advice

following a full submission assessed under the end of life medicine process:

cemiplimab (Libtayo®) is accepted for restricted use within NHSScotland.

Indication under review: In combination with platinum-based chemotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) expressing PD-L1 (in ≥1% of tumour cells) with no EGFR, ALK or ROS1 aberrations, who have:

  •   locally advanced NSCLC who are not candidates for definitive chemoradiation, or
  •   metastatic NSCLC

SMC restriction: Treatment with cemiplimab is subject to a stopping rule of a maximum of 36 three-weekly cycles.

Evidence from a double-blind, phase III study demonstrated that cemiplimab plus chemotherapy improved overall survival (OS) compared with placebo plus chemotherapy. Indirect comparisons suggest similar OS and progression-free survival (PFS) compared with pembrolizumab plus chemotherapy, which is a relevant treatment for metastatic NSCLC.

This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.

This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.

Medicine details

Medicine name:
cemiplimab (Libtayo)
SMC ID:
SMC2906
Indication:

In combination with platinum‐based chemotherapy for the first‐line treatment of adult patients with NSCLC expressing PD-L1 (in ≥ 1% of tumour cells), with no EGFR, ALK or ROS1 aberrations, who have:

  • locally advanced NSCLC who are not candidates for definitive chemoradiation, or
  • metastatic NSCLC
Pharmaceutical company
Regeneron Pharmaceuticals Inc
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Status
Restricted
Date advice published
09 November 2026